Immuno-oncology drug CJRB-101, Phase 1/2 clinical trial in US/Korea terminated early (2026.05.12). Phase 2 not proceeding; only ongoing patients continue on humanitarian basis.
Q1 2026 revenue: KRW 0.78bn (down 14% YoY from KRW 0.91bn), operating loss KRW 5.34bn, net loss KRW 5.13bn.
R&D expense KRW 3.33bn (425.6% of revenue); accumulated deficit KRW 148.5bn vs equity KRW 48.1bn.
Cash and cash equivalents KRW 2.13bn, short-term financial assets KRW 42bn; net cash position KRW 36.6bn. No debt ratio (net cash).
No dividends. Largest shareholder CJ CheilJedang holds 61.9%.